Fig 1: Potential biomarkers for EOPE and LOPE. A, UMAP plots showing expression levels of known and novel biomarkers in the atlas of maternal‐foetal interface. B, Plasma EBI3 levels were elevated in EOPE (n = 8) but not LOPE (n = 6) and presented positively correlation tendency to uric acid and proteinuria. The bioinformatic, experimental verified EBI3 expression levels and the correlation to uric acid and proteinuria were presented from left to right, respectively. C, A network of secretory proteins and their targets. The colour of the gene name indicates the signalling pathways to which it belongs; the node shape indicates the cellular location of the protein; the filled colour of each node indicates the expression change of the gene in EOPE patients; the red star indicates the proteins discussed in the main text. D, Scatter plots showing the bioinformatic (top panel) and qPCR verified (bottom panel) expression levels of newly identified biomarkers for LOPE (For experimental data, LOPE_S, n = 4; NC for LOPE_S, n=4; LOPE_NS, n = 12; NC for LOPE_NS, n=12). E, Scatter plots showing the bioinformatic (top panel) and qPCR verified (bottom panel) expression levels of newly identified biomarkers that could be used to distinguish the severity of LOPE (For experimental data, severe and non‐severe LOPE, n = 4). Data are presented as mean ± SEM and compared by the empirical Bayes moderated t‐statistics test (for bioinformatic data) and Student's t‐test (for experimental data). *P < .05, **P < .01, ***P < .001. EO_N, the normal group corresponding to EOPE; FC, fold change; LOPE_S, severe LOPE; LO_N, the normal group corresponding to LOPE and LOPE_NS, non‐severe LOPE